Table 1.
Studies measuring ox-LDL included in the meta-analysis.
| Author, year, country | Design of study | Follow-up | Type of surgery | Control (n) | Outcome | Patients' characteristic Age Sex |
No. of patients | |
|---|---|---|---|---|---|---|---|---|
| ox-LDL methods of ox-LDL assessment | BMI change (%) | |||||||
| Carmona-Maurici et al., 2020 [24] Spain |
Prospective observational cohort study | 6 months 12 months |
Laparoscopic RYGB or SG | — | Significant decrease in ox-LDL levels (Mercodia ox-LDL kit) |
-32.27 | Obese patients with atheromatous plaque 51.8 ± 1.8 years old 18 (F)/14 (M) |
32 |
| -33.91 | Obese patients without atheromatous plaque 43.5 ± 1.8 years old 29 (F)/5 (M) |
34 | ||||||
| Ho et al., 2021 [25] | Prospective, observational study | 6 months 12 months |
RYGB, SG, or omega loop bypass | Patients seeking weight management [16] | Unchanged (Mercodia ox-LDL kit) |
-29.95 | Morbid obesity patients 50.1 ± 10 years old - |
59 |
| Coimbra et al., 2019 [26] | Observational study | 13 months | Laparoscopic adjustable gastric banding (LAGB) | Healthy volunteers [17] | Significant decrease in ox-LDL levels (Mercodia ox-LDL kit) |
-11.85 | Obese patients 49.03 ± 10.71 years old 18 (F)/2 (M) |
20 |
| Gomez-Martin et al., 2018 [27] | Observational study | 6 months 12 months |
SG | Women matched for age and cardiovascular risk (modified Mediterranean diet) [18] |
Significant decrease in ox-LDL levels after 12 months in comparison to baseline and control group (Mercodia ox-LDL kit) |
-28.83 | Obese women 46 ± 9 years old |
20 |
| Laparoscopic RYGB | -33.82 | Obese women 48 ± 8 years old |
20 | |||||
| Kelly et al., 2016 [28] | Longitudinal cohort | 6 months 12 months |
RYGB or vertical SG | — | Significant decrease in ox-LDL levels at 12 months (Mercodia ox-LDL kit) |
-32.6 | Adolescents with severe obesity 16.5 ± 1.6 years old 10 (M)/29 (F) |
39 |
| 3 months 12 months |
Laparoscopic RYGB | — | Unchanged (Mercodia ox-LDL kit) |
-35.6 | Adolescents with severe obesity 16.5 ± 1.6 years old 3 (M)/10 (F) |
13 | ||
| Müller-Stich et al., 2015 [29] | Prospective cohort | 6 months 12 months |
RYGB | — | Unchanged (OxiSelect MDA-LDL-quantitation kit) |
-25 | Patients with BMI more than 35 kg/m2 and insulin-dependent T2DM 58.6 ± 6.1 years old 10 (M)/10 (F) |
20 |
| Van der Schueren et al., 2015 [30] | Observational study | 4 months 7 years |
Laparoscopic RYGB | Lean controls [24] |
Significant decrease in ox-LDL levels at 7 years (Mercodia ox-LDL kit) |
-26.6 | Obese patients 40 ± 14 years old 5 (M)/12 (F) |
17 |
| Julve et al., 2014 [31] | Observational study | 6 months 12 months |
RYGB | — | Significant decrease in ox-LDL levels (Mercodia ox-LDL kit) |
— | Obese patients 20-60 years old 15 (F)/6 (M) |
21 |
| Martín-Rodríguez et al., 2014 [32] | Prospective cohort | 12 months | Bariatric surgery | Lean Control subjects [30] |
Significant decrease in ox-LDL levels (immunodiagnostic system) | -31.37 | Obese patients without metabolic syndrome 40 ± 9 years old 19(F)/4(M) |
23 |
| -16.33 | Obese patients with metabolic syndrome 42 ± 10 years old 34(F)/5(M) |
39 | ||||||
| Garrido-Sánchez et al., 2008 [33] | Observational study | 7 months | Biliopancreatic diversion, or RYGB | Healthy, nonobese persons [11] |
Significant decrease in ox-LDL levels (Mercodia ox-LDL kit) |
-33.9 | Morbidly obese patients with: | 21 |
| Normal fasting glucose 39.5 ± 11 years old 14(F)/7(M) | ||||||||
| -30.39 | Impaired fasting glucose 44.1 ± 10.6 years old 21(F)/10(M) |
31 | ||||||
| -30.74 | Type 2 diabetes 44.5 ± 7.4 years old 14(F)/7(M) |
21 | ||||||
| Uzun et al., 2004 [34] | Observational study | 6 months | Open Swedish adjustable gastric band (SAGB) | Significant decrease in ox-LDL levels (Mercodia ox-LDL kit) |
-24.24 | Morbidly obese patients 35.1 ± 13.1 years old 10(F)/10(M) |
20 | |
| Laparoscopic SAGB | — | Significant decrease in ox-LDL levels (Mercodia ox-LDL kit) |
-24.27 | Morbidly obese patients 34.6 ± 9 years old 11(F)/9(M) |
20 | |||